Company Active LTD

Company profile

Biotoolomics Limited

BioToolomics::Specialising in high performance bioprocessing chromatography media & disposable columns for the purification of antibody and biopharmaceutical drugs....

Biotoolomics offers ready-to-use disposable chromatography technology for the purification of biopharmaceutical drugs.Our products and services strongly focus on the core theme of “ready-to-use, disposable, high performance and high flexibility.”

CRN
05635708
Founded
2005
Age
20

Overview

Legal name
BIOTOOLOMICS LIMITED
Region
North East England
Registered address
UNIT 30A
NUMBER ONE INDUSTRIAL ESTATE
CONSETT
ENGLAND
DH8 6TJ
Insolvency history
No

Latest accounts

Financial period: 1 Jan 2024 to 31 Dec 2024

FILLETEDACCOUNTS
Turnover
Unknown
Profit / Loss
Unknown
Employees
10

Company events

Reference milestones and recent Companies House filing stream events.

6 events
08 Dec
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

30 Sep
2026

Accounts due

Accounts Due

Next accounts due date

24 Nov
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Dec
2024

Accounts filed

Accounts

Last accounts made up date

20 Sep
2024

Accounts With Accounts Type Total Exemption Full

Accounts Analysed

AA | Transaction MzQzNjY5ODAxOGFkaXF6a2N4

Published 20 Sep 2024 01:39

24 Nov
2005

Incorporated

Inception

Company registered at Companies House

Public funding

8 awards
First funded
2010
Funded years
2010, 2015, 2018, 2019, 2023, 2024
Age at first award
4 years

Projects

2024 EU-Funded Lead participant

PharmEco: Advancing Safe and Sustainable by Design Practices in Pharmaceutical Manufacturing

1 Nov 2024 to 31 Oct 2030

Awarded
£211,364
Total cost £211,364

PHARMECO is supported by the Innovative Health Initiative Joint Undertaking (IHI JU). The JU receives support from the European Union’s Horizon Europe research and innovation programme and COCIR, EFPIA, Europa Bío, MedTech Europe, and Vaccines Europe. The project's overall objective is to revolutionize pharmaceutical manufacturing towards sustainability b...

2023 Collaborative R&D

Elevated temperature mediated OLigo synthesis using LIgase and resin tEchnology - OLLIE

1 Dec 2023 to 31 Jan 2026

Awarded
£245,176
Total cost £350,251

The manufacture of medicines was brought to the fore during the recent pandemic. The urgency of being able to produce the quantities and quality of medicine in a short period of time focussed minds across academia and industry. A further focus for the public in recent years has been the protection of our environment and introduction of practises reducing ...

2023 Collaborative R&D Lead participant

Manufacturing high purity mRNA at significantly reduced cost

1 Jun 2023 to 31 May 2024

Awarded
£70,004
Total cost £100,005

Currently mRNA medicines are synthesized through in vitro transcription (IVT) reaction. The presence of double-stranded RNA (dsRNA) is one of the major quality concerns to mRNA medicines. Besides, the raw material cost in IVT reactions is very high but their utilisation efficiency is very low. This collaborative research project aims to use more cost-effe...

2019 Feasibility Studies Lead participant

Novel technology to purify viral vectors free of empty capsids for gene therapy use at manufacturing scale

1 Apr 2019 to 31 Dec 2020

Awarded
£307,997
Total cost £439,996

Gene therapy has formed one of the most advanced medical technology in the modern precision medicine area. It has shown some unique advantages in curing certain diseases. There is a growing demand of high quality viral medicines to be manufactured with efficient and cost-effective methods. This Research Project proposes a highly efficient chromatography b...

2019 Collaborative R&D

Disruptive antibody purification process employing novel inexpensive chromatography materials

1 Feb 2019 to 31 Jan 2022

Awarded
£597,520
Total cost £853,600

While biotherapeutics offer potential treatments for some of the most debilitating diseases, the development and manufacture of these potentially life changing treatments is risky, technically challenging and expensive. This project will develop novel polymer composite materials specifically for the efficient and cost-effective manufacturing of antibody d...

2018 Feasibility Studies Lead participant

Very efficient platform purification process for gene therapy medicines using innovative chromatography technology

1 Feb 2018 to 31 Jan 2019

Awarded
£67,078
Total cost £95,826

Gene therapy has formed one of the most advanced medical technology in the modern precision medicine area. It has shown some unique advantages in curing certain diseases. There is a growing demand of high quality viral medicines to be manufactured with efficient and cost-effective processes. This feasibility study project proposes a much efficient purific...

2015 Collaborative R&D

Much-efficient and cost-effective manufacturing of antibody biotherapeutics employing integrated negative chromatography technology

1 Jul 2015 to 30 Jun 2018

Awarded
£279,704
Total cost £466,174

The current platform antibody purification process deployed in the bioprocesing industry becomes less efficient and less cost-effective to match with high titre upstream technologies. Based on previous feasibility studies using model antibodies, the key aim and objective of this project is to investigate negative chromatography based technologies using re...

2010 Legacy RDA Grant for R&D Lead participant

Negative Chromatography Technology for Cost Effective manufacturing of Antibody Biopharmaceuticals

1 Jun 2010 to 31 Dec 2014

Awarded
£250,000
Total cost £653,150

BioToolomics Ltd is a life science company offering cutting-edge solutions to the cost-effective purification of biopharmaceutical drugs. The project is tilted "Negative chromatography technology for the cost-effective manufacturing of antibody biopharmaceuticals". In simple term, according to this technology, an antibody drug produced in cell culture bro...

Product types

Collaborative R&D EU-Funded Feasibility Studies Legacy RDA Grant for R&D